

Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis

Karunaratne K, Ahrabian D, Monaghan B, *et al.* Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis. *BMJ Neurol Open* 2021;3:e000096. doi:10.1136/bmjno-2020-000096

The article has been corrected since it was first published. The published version misspelled one of the authors' names as 'Bernadette Monaghan' which has been now amended to 'Bernadette Monaghan'.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

BMJ Neurol Open 2021;3:e000096corr1. doi:10.1136/bmjno-2020-000096corr1

